Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

Registry Results See Less PVL, Pacemakers With Acurate neo2

Shelley Wood

November 29, 2022

Presentation TCT 2022

TCT 363: Incidence and timing of device related thrombus in percutaneous implantable cardiac devices: A systematic review and meta-analysis

Presenter: Richard Jung

September 19, 2022

Presentation TCT 2022

TCT 362: Direct-acting Oral Anticoagulants versus Vitamin K Antagonists in Patients Undergoing Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-analysis

Presenter: Khawaja Akhtar

September 19, 2022

Presentation TCT 2022

TCT 361: On the Likelihood of Leaflet Thrombosis following Transcatheter Pulmonary Valve Replacement

Presenter: Mina Shafiei

September 19, 2022

Presentation TCT 2022

TCT 360: The Importance of Leaflet Design in Initiation and Growth of Leaflet Thrombosis in Transcatheter Aortic Valves

Presenter: Ali Azadani

September 19, 2022

Presentation TCT 2022

TCT 359: Continued Oral Anticoagulation With Non-Vitamin K Antagonist Oral Anticoagulants Versus Vitamin K Antagonists in Transcatheter Aortic Valve Implantation

Presenter: Norman Mangner

September 19, 2022

News Conference News TCT 2022

As Time Goes By, Post-TAVI Thrombus Becomes More OAC Resistant

Michael O'Riordan

September 18, 2022

Presentation TCT 2022

Pathology of Self-Expanding Transcatheter Aortic Valve Failure and Hypo-Attenuated Leaflet Thickening (HALT)

Presenter: Yu Sato

September 17, 2022

News Daily News

Subclinical Thrombosis After TAVI Benign, at Least to 3 Years

Michael O'Riordan

June 07, 2022

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Todd Neale

April 05, 2022

News Conference News ACC 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Michael O'Riordan

April 04, 2022

News Daily News

Subclinical Leaflet Thrombosis After TAVI Linked to Higher Mortality

Michael O'Riordan

March 10, 2022

News Conference News

Longer-Term LRT Results ‘Encouraging’ for TAVI in Low-risk Patients

Todd Neale

March 01, 2022

Video

» Interview

Pathology of Self-Expanding Transcatheter Aortic Valve Failure and Hypo-Attenuated Leaflet Thickening (HALT)

September 17, 2022

Advertisement

Registry Results See Less PVL, Pacemakers With Acurate neo2

TCT 363: Incidence and timing of device related thrombus in percutaneous implantable cardiac devices: A systematic review and meta-analysis

TCT 362: Direct-acting Oral Anticoagulants versus Vitamin K Antagonists in Patients Undergoing Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-analysis

TCT 361: On the Likelihood of Leaflet Thrombosis following Transcatheter Pulmonary Valve Replacement

TCT 360: The Importance of Leaflet Design in Initiation and Growth of Leaflet Thrombosis in Transcatheter Aortic Valves

TCT 359: Continued Oral Anticoagulation With Non-Vitamin K Antagonist Oral Anticoagulants Versus Vitamin K Antagonists in Transcatheter Aortic Valve Implantation

As Time Goes By, Post-TAVI Thrombus Becomes More OAC Resistant

Pathology of Self-Expanding Transcatheter Aortic Valve Failure and Hypo-Attenuated Leaflet Thickening (HALT)

Subclinical Thrombosis After TAVI Benign, at Least to 3 Years

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Subclinical Leaflet Thrombosis After TAVI Linked to Higher Mortality

Longer-Term LRT Results ‘Encouraging’ for TAVI in Low-risk Patients

Pathology of Self-Expanding Transcatheter Aortic Valve Failure and Hypo-Attenuated Leaflet Thickening (HALT)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content